ArticleStatistics in medicine2017
A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials.
Article in Statistics in medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 35 citations in OpenAlex.
- A narrative review of adaptive Phase I/II clinical trial designs for drug combinations in oncology.Frontiers in oncology · 2026Review
- Toxicity Adaptive Lists Design: A Practical Design for Phase I Drug Combination Trials in Oncology.JCO precision oncology · 2024Article
- Applications of the partial-order continual reassessment method in the early development of treatment combinations.Clinical trials (London, England) · 2024Article
- A new function for drug combination dose finding trials.Scientific reports · 2024Article
- A Bayesian adaptive design for dual-agent phase I-II oncology trials integrating efficacy data across stages.Biometrical journal. Biometrische Zeitschrift · 2023Article
- Evaluation of phase I clinical trial designs for combinational agents along with guidance based on simulation studies.Journal of applied statistics · 2023Review
- Modeling synergism in early phase cancer trials with drug combination with continuous dose levels: is there an added value?Brazilian journal of biometrics · 2022Article
- Combining cytotoxic agents with continuous dose levels in seamless phase I-II clinical trials.Journal of the Royal Statistical Society. Series C, Applied statistics · 2022Article
- A nonparametric Bayesian method for dose finding in drug combinations cancer trials.Statistics in medicine · 2022Article
- Accuracy and Safety of Novel Designs for Phase I Drug-Combination Oncology Trials.Statistics in biopharmaceutical research · 2022Article
- Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information.Biometrical journal. Biometrische Zeitschrift · 2021Article
- A Bayesian seamless phase I-II trial design with two stages for cancer clinical trials with drug combinations.Biometrical journal. Biometrische Zeitschrift · 2020Article
- A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Ordinal Toxicity Grades.Stats · 2020Article
- Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents.Biometrical journal. Biometrische Zeitschrift · 2019Article
- AAA: triple adaptive Bayesian designs for the identification of optimal dose combinations in dual-agent dose finding trials.Journal of the Royal Statistical Society. Series C, Applied statistics · 2019Article
- Two-stage design for phase I-II cancer clinical trials using continuous dose combinations of cytotoxic agents.Journal of the Royal Statistical Society. Series C, Applied statistics · 2019Article
- Accelerating anticancer drug development - opportunities and trade-offs.Nature reviews. Clinical oncology · 2018Review
- A Bayesian Adaptive Design in Cancer Phase I Trials using Dose Combinations in the Presence of a Baseline Covariate.Journal of probability and statistics · 2018Article
- A Bayesian adaptive design for cancer phase I trials using a flexible range of doses.Journal of biopharmaceutical statistics · 2018Article
- Dose Finding for Drug Combination in Early Cancer Phase I Trials using Conditional Continual Reassessment Method.Journal of biometrics & biostatistics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
We present a cancer phase I clinical trial design of a combination of two drugs with the goal of estimating the maximum tolerated dose curve in the two-dimensional Cartesian plane. A parametric model is used to describe the relationship between the doses of the two agents and the probability of dose limiting toxicity. The model is re-parameterized in terms of the probabilities of toxicities at dose combinations corresponding to the minimum and maximum doses available in the trial and the interaction parameter. Trial design proceeds using cohorts of two patients receiving doses according to univariate escalation with overdose control (EWOC), where at each stage of the trial, we seek a dose of one agent using the current posterior distribution of the MTD of this agent given the current dose of the other agent. The maximum tolerated dose curve is estimated as a function of Bayes estimates of the model parameters. Performance of the trial is studied by evaluating its design operating characteristics in terms of safety of the trial and percent of dose recommendation at dose combination neighborhoods around the true MTD curve and under model misspecifications for the true dose-toxicity relationship. The method is further extended to accommodate discrete dose combinations and compared with previous approaches under several scenarios. Copyright © 2016 John Wiley & Sons, Ltd.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.